Drug packaging regs

Packaging for an approved new drug may be affected by FDA's proposed amendments to its new drug regulations. At issue is when any change to an approved new drug requires the filing of a supplemental new drug application (SNDA), when FDA prior approval is needed, and when a notice in an annual report is sufficient.

FDA proposed creating four reporting categories (instead of the current three). Among other proposed amendments: Changes to a container and closure system that may affect the purity of a drug require submission of an SNDA and prior FDA approval. Changes that are not expected to affect the quality of the drug require submission of an SNDA at least 30 days prior to making the change (but not FDA prior approval, a relaxation of the current rule), unless they are specifically covered in another category. The proposal indicates FDA has heightened its reporting requirements for changes within containers and closure systems for sterile liquid drugs, while relaxing reporting requirements for changes to containers and closure systems for nonsterile liquid and solid-dose forms.

Need help with your packaging project?
We’ve done the legwork to identify and vet experienced packaging and processing consultants you can contact directly for your next project. Decades of combined experience in packaging line engineering, machinery selection, package and materials development, and food processing operations.
See your advisor options now.
Need help with your packaging project?
Don't miss Packaging Recycling Summit 2026
Where innovation meets sustainability. Join the leading forum for packaging recycling professionals, featuring cutting-edge solutions, expert insights, and the connections you need to advance the circular economy. Secure your spot today.
Discover More
Don't miss Packaging Recycling Summit 2026